Vistagen Therapeutics vs Xenon Pharmaceuticals
VTGN and XENE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How VTGN and XENE compare
Xenon Pharmaceuticals is the larger company, worth 489 times as much as Vistagen Therapeutics ($3.9B against $8.0M).
Vistagen Therapeutics scores higher on the StockData Score (9 against 7 for Xenon Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | VTGN | XENE |
|---|---|---|
| Size and price | ||
| Market cap | $8.0M | $3.9B |
| Share price | $0.180 | $40.48 |
| Change, 1 year | −95.6% | 2.0% |
| Change, 5 years | −99.7% | 39.6% |
| Beta (5Y) | 1.31 | 0.62 |
| Employees | 41 | 370 |
| StockData Score | ||
| Total score | 9 (better) | 7 |
| Valuation score | 3 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.4× | – |
| P/B | 0.5× (better) | 3.4× |
| FCF yield | – | −9.1% |
| Fair value | $0.660 | – |
| Margin of safety | 72.7% | – |
| Growth | ||
| Revenue growth (TTM) | – | −100% |
| Revenue growth, 5Y average | 3.1% (better) | −25.3% |
| Profitability | ||
| Operating margin | −2542% | – |
| Net margin | −2475% | – |
| Return on equity | −145% | −50.3% (better) |
| Return on invested capital | – | −251% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 2.64 | 21.19 (better) |
| Altman Z-score | −37.10 | 41.77 (better) |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 26.5% | 104% |
| Held by insiders | 0.52% | 0.17% |
| Insider net buying, 12 months | – | −$20.3M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 5.6% | 7.6% |
Go deeper
- VTGN stock overview
- VTGN income statement
- VTGN valuation and score
- XENE stock overview
- XENE income statement
- XENE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.